| Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology TW Flaig, PE Spiess, N Agarwal, R Bangs, SA Boorjian, ... Journal of the National Comprehensive Cancer Network 18 (3), 329-354, 2020 | 505 | 2020 |
| Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology RJ Motzer, E Jonasch, N Agarwal, A Alva, M Baine, K Beckermann, ... Journal of the National Comprehensive Cancer Network 20 (1), 71-90, 2022 | 330 | 2022 |
| NCCN guidelines insights: kidney cancer, version 2.2020: featured updates to the NCCN guidelines RJ Motzer, E Jonasch, MD Michaelson, L Nandagopal, JL Gore, S George, ... Journal of the National Comprehensive Cancer Network 17 (11), 1278-1285, 2019 | 207 | 2019 |
| NCCN guidelines insights: kidney cancer, version 1.2021: featured updates to the NCCN guidelines RJ Motzer, E Jonasch, S Boyle, MI Carlo, B Manley, N Agarwal, A Alva, ... Journal of the National Comprehensive Cancer Network 18 (9), 1160-1170, 2020 | 195 | 2020 |
| NCCN Guidelines® insights: bladder cancer, version 2.2022: featured updates to the NCCN guidelines TW Flaig, PE Spiess, M Abern, N Agarwal, R Bangs, SA Boorjian, ... Journal of the National Comprehensive Cancer Network 20 (8), 866-878, 2022 | 135 | 2022 |
| Obesity diminishes response to PD-1-based immunotherapies in renal cancer SK Boi, RM Orlandella, JT Gibson, WJ Turbitt, G Wald, L Thomas, ... Journal for immunotherapy of cancer 8 (2), 2020 | 58 | 2020 |
| Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer G Sonpavde, N Agarwal, GR Pond, RJ Nagy, RH Nussenzveig, AW Hahn, ... Cancer 125 (9), 1459-1469, 2019 | 46 | 2019 |
| Integrating geriatric assessment into routine gastrointestinal (GI) consultation: The Cancer and Aging Resilience Evaluation (CARE) GR Williams, KM Kenzik, M Parman, M Al-Obaidi, L Francisco, ... Journal of geriatric oncology 11 (2), 270-273, 2020 | 44 | 2020 |
| Bronchoscopy can be done safely in patients with thrombocytopenia L Nandagopal, M Veeraputhiran, T Jain, AO Soubani, CA Schiffer Transfusion 56 (2), 344-348, 2016 | 39 | 2016 |
| Circulating biomarkers in bladder cancer L Nandagopal, G Sonpavde Bladder Cancer 2 (4), 369-379, 2016 | 32 | 2016 |
| Investigational MET inhibitors to treat Renal cell carcinoma L Nandagopal, GP Sonpavde, N Agarwal Expert Opinion on Investigational Drugs 28 (10), 851-860, 2019 | 22 | 2019 |
| 385 A first-in-human study of lemzoparlimab, a differentiated anti-CD47 antibody, in subjects with relapsed/refractory malignancy: initial monotherapy results J Berlin, W Harb, A Adjei, Y Xing, P Swiecicki, M Seetharam, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 12 | 2020 |
| Treatment approaches of hard-to-treat non-Hodgkin lymphomas L Nandagopal, A Mehta Expert Review of Hematology 10 (3), 259-273, 2017 | 11 | 2017 |
| Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy. G Sonpavde, RJ Nagy, AO Sartor, GR Pond, TS Gourdin, L Nandagopal, ... Journal of Clinical Oncology 35 (6_suppl), 149-149, 2017 | 11 | 2017 |
| Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration … SK Subudhi, BA Siddiqui, JJ Maly, L Nandagopal, ET Lam, YE Whang, ... Journal of Clinical Oncology 39 (15_suppl), TPS5088-TPS5088, 2021 | 10 | 2021 |
| Overview of current and future adjuvant therapy for high-risk localized renal cell carcinoma L Nandagopal, G Naik, G Sonpavde Current Treatment Options in Oncology 19, 1-15, 2018 | 9 | 2018 |
| Correlation between Dt/V derived from ionic dialysance and blood-driven Kt/V of urea in African-American hemodialysis patients, based on body weight and ultrafiltration volume W Gebregeorgis, ZY Bhat, N Pradhan, SD Migdal, L Nandagopal, ... Clinical kidney journal 11 (5), 734-741, 2018 | 8 | 2018 |
| Change in neutrophil to lymphocyte ratio (NLR) as a predictor of treatment failure in renal cell carcinoma patients: Analysis of the IROC (Investigating RCC Outcomes) cohort. A Basu, A Phone, T Bice, P Sweeney, L Acharya, Y Suri, AS Chan, ... Journal of clinical oncology 39 (6_suppl), 344-344, 2021 | 7 | 2021 |
| Multi-institutional analysis of the clinical and genomic characteristics of black patients with metastatic hormone-sensitive prostate cancer MN Freeman, A Jang, J Zhu, F Sanati, L Nandagopal, D Ravindranathan, ... The Oncologist 27 (3), 220-227, 2022 | 6 | 2022 |
| Comprehensive genomic profiling of cell-free DNA in men with advanced prostate cancer: differences in genomic landscape based on race R Zimmerman, MA Bilen, EI Heath, L Nandagopal, U Swami, A Kessel, ... The Oncologist 27 (10), e815-e818, 2022 | 5 | 2022 |
NEERAJ Agarwaluniversity of utahVerified email at hci.utah.edu
